| Literature DB >> 16362793 |
A Ephrem1, N Misra, G Hassan, S Dasgupta, S Delignat, J-P Duong Van Huyen, S Chamat, F Prost, S Lacroix-Desmazes, S V Kavery, M D Kazatchkine.
Abstract
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16362793 DOI： 10.1007/s10238-005-0079-y
Source DB: PubMed Journal: Clin Exp Med ISSN： 1591-8890 Impact factor: 3.984